HOME  | CONTACT  | PATIENT LOGIN  | CLINIC LOGIN  | FAQ
  • PATIENTS &
    HEALTHY VOLUNTEERS
  • INVESTIGATORS
  • CROS / SPONSORS
  • CAREERS
  • TRIAL ALERTS

TRIALS SEARCH
      
  • HEALTH NEWS

  • RSS FEEDS

  • ABOUT TRIALS

  • LINK TO US


View Clinical Trial (Medical Research Study)


An Open-Label Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-072 and Ribavirin (RBV) in Treatment-Naive Subjects With Genotype 1 Chronic Hepati

This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials

Signup
Browse Studies

City:   Seattle
State:   Washington
Zip Code:   98101
Conditions:   Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1
Purpose:   A 12-week study of combination direct-acting antiviral agents (DAAs) and Ribavirin (RBV) in subjects with chronic Hepatitis C Virus (HCV).
Study Summary:  
Criteria:   Inclusion Criteria - Chronic hepatitis C, genotype 1 infection (IL28B rs12979860 genotype C/C). - Liver biopsy within 3 years with histology consistent with HCV-induced liver damage, with no evidence of cirrhosis or liver pathology due to any cause other than chronic Hepatitis C Virus. - Treatment naïve male or female between the ages of 18 and 65. - Females must be post-menopausal for at least 2 years or surgically sterile. - Be in a condition of general good health, as perceived by the investigator, other than Hepatitis C Virus infection. Exclusion Criteria - Significant sensitivity to any drug. - Use of herbal supplements within 2 weeks prior to study drug dosing. - Positive screen for drugs and alcohol. - Positive Hepatitis surface Antigen and anti-Human Immunodeficiency Virus Antibody. - Use of CYP3A, CYP2C8, and OATP1B1 enzyme inducers or inhibitors within 1 month of dosing. - Prior treatment with any investigational or commercially available anti-Hepatitis C Virus agents. - Abnormal laboratory tests.
NCT ID:   NCT01221298
Primary Contact:   Study Director
Daniel Cohen, MD
Abbott

Backup Contact:   N/A
Location Contact:   Seattle, Washington 98101
United States



There is no listed contact information for this specific location.

Site Status: N/A

Click here to see:
  • Clinical trials for Hepatitis C in Seattle, Washington

Data Source:   ClinicalTrials.gov
Date Processed:   May 24, 2013
Modifications to this listing:   Only selected fields are shown, please use the link below to view all information about this clinical trial.
Click to view Full Listing


  • NEARBY STUDIES

Within 25 Miles

Antidepressant Induced Sexual Dysfunction - Seattle WA

Bipolar Disorder - Seattle WA

Pediatric Depression - Kirkland WA

Pediatric Depression - Seattle WA

Generalized Anxiety Disorder - Seattle WA

Crohn's Disease - Seattle WA

Depression - Seattle WA

Treatment Resistant Depression - Seattle WA

Gout - Port Orchard WA

Binge Eating Disorder - Seattle WA

Postherpetic Neuralgia (Post-shingles pain) - Tacoma WA

Multiple Sclerosis - Seattle WA

Low Back Pain and Constipation - Bothell WA

Anti-Depressant Induced Sexual Dysfunction - Seattle WA

Uncontrolled Angina (Adult Stem Cell Research) - Seattle WA

Uncontrolled Angina (Adult Stem Cell Research) - Seattle WA

Irritable Bowel Syndrome (with diarrhea) - Seattle WA

Brain Tumor (Glioblastoma) - Seattle WA

Chronic Sciatic Pain - Bellevue WA

Adult ADHD - Seattle WA

Within 50 Miles

Within 100 Miles

Irritable Bowel Syndrome (with diarrhea) - Wenatchee WA

 
Clinical Connections Home | Investigators | CROs / Sponsors | Clinical Trials Notification | Search Clinical Trials | About Clinical Trials | Links | Terms And Conditions | Sitemap | Suggestions / Feedback
© 1998-2013 | All trademarks are property of their legal owners. | All Rights Reserved

ClinicalConnection.com is a resource that provides individuals with information regarding clinical trials that are being conducted worldwide.

ClinicalConnection.com does not conduct these clinical trials nor endorse them. Please consult your doctor or physician before participating.